A new role for E2F1 in DNA repair: all for the greater good.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition.BMC cancer · 2025
   Article
2. RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
   Article
3. RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1.Genes & development · 2016
   Article
4. Inducible deletion of epidermal Dicer and Drosha reveals multiple functions for miRNAs in postnatal skin.Development (Cambridge, England) · 2012
   Article

Corrections and comments

• Comment on
  E2F1 promotes the recruitment of DNA repair factors to sites of DNA double-strand breaks.2011

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as